Terminal
Stocks
Spotlight
Research

Stocks
Healthcare
NASDAQ
BCRX

Market Cap: $2.06B

BI

BioCryst Pharmaceuticals, Inc.

BCRX

NASDAQ (NASDAQ Global Select)USD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive Patents Earnings Surprise

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Advertisers Brokers Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Financials

Profitability

Gross Profit Margin23.52%

EBITDA Margin-32.20%

EBIT Margin-32.84%

Pre-tax Margin-40.53%

Net Profit Margin-40.90%

Earnings Yield-18.62%

Valuation Multiples

Price / Book-4.55

Price / Sales2.19

Price / Earnings-5.64

PEG0.00

Forward PEG0.05

EV / Sales2.47

EV / EBITDA-7.66

EV / Operating Cash Flow6.44

EV / Free Cash Flow6.49

Price / Free Cash Flow5.78

Price / Operating Cash Flow5.74

Cash Flow & Capital

Free Cash Flow / Share$1.4

Operating Cash Flow / Share$1.41

Free Cash Flow Yield17.30%

Capex / Revenue0.29%

Capex / Operating Cash Flow0.77%

Capex / Depreciation0.46

Stock Compensation / Revenue12.96%

Dividend Payout Ratio0.00%

Dividend Yield0.00%

Liquidity & Leverage

Current Ratio2.32

Quick Ratio2.29

Cash Ratio0.74

Debt / Assets0.73

Debt / Capital-9.22

Debt / Equity-0.90

Long-Term Debt / Capital-6.71

Debt / Market Cap19.16%

Net Debt / EBITDA-0.84

Solvency Ratio-0.37

Financial Leverage-1.23

Efficiency & Working Capital

Asset Turnover1.69

Fixed Asset Turnover43.41

Inventory Turnover118.79

Receivables Turnover8.49

Payables Turnover62.78

Days Sales Outstanding42.98

Days Inventory Outstanding3.07

Days Payables Outstanding5.81

Operating Cycle46.05

Cash Conversion Cycle40.24

Working Capital Turnover4.14

Returns & Quality

Return on Equity1.02%

Return on Assets-68.96%

Return on Invested Capital-88.96%

ROCE-89.73%

Return on Tangible Assets-68.96%

Operating Return on Assets-61.23%

Income Quality-1.34

Tax Burden1.01

Interest Burden1.23

Balance Sheet & Intrinsic Metrics

Enterprise Value$2.32B

Invested Capital$297.5M

Working Capital$275.84M

Tangible Asset Value$-454.29M

Net Current Asset Value$-527.46M

Graham Net-Net-$2.25

Book Value / Share-$1.79

Tangible Book Value / Share-$1.79

Cash / Share$1.39

Financial Health Scores

Piotroski Score5

Altman Z-Score-3.69

Revenue$940.61M

EBIT$-308.91M

Market Cap$2.11B

Working Capital$275.84M

Retained Earnings$-2.15B

Total Assets$557.85M

Total Liabilities$1.01B